Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Niacin SCHEMBL810780 | 0.85 | KMT2A (0.64) | LMNAKMT2ATDP1GAAALDH1A1 | |
| Niacin SCHEMBL6703843 | 0.84 | LMNA (0.63) | LMNAKMT2ATDP1GAAALDH1A1 | |
| Niacin SCHEMBL810760 | 0.83 | ALDH1A1 (0.57) | LMNAKMT2ATDP1GAAALDH1A1 | |
| SCHEMBL811047 | 0.83 | LMNA (0.66) | LMNAKMT2ATDP1GAAALDH1A1 | |
| SCHEMBL536532 | 0.82 | ALDH1A1 (0.53) | LMNAKMT2ATDP1ALDH1A1HCAR2 | |
| SCHEMBL10357917 | 0.82 | ALDH1A1 (0.53) | LMNAKMT2ATDP1ALDH1A1HCAR2 | |
| SCHEMBL1133837 | 0.82 | ALDH1A1 (0.53) | LMNAKMT2ATDP1ALDH1A1HCAR2 | |
| Benzyl Nicotinate SCHEMBL30432197 | 0.81 | TDP1 (0.91) | LMNAKMT2ATDP1GAAALDH1A1 | |
| Malic Acid SCHEMBL810935 | 0.81 | ALDH1A1 (0.66) | LMNAKMT2ATDP1GAAALDH1A1 | |
| Malic Acid SCHEMBL31380098 | 0.81 | ALDH1A1 (0.66) | LMNAKMT2ATDP1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160220536-A1 | USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTOR OVEREXPRESSION | UNIV OHIO (US) | 2016-08-04 | — | — | US | disclosed |
| US-9326972-B2 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | OHIO UNIVERSITY (US) | 2016-05-03 | — | — | US | disclosed |
| US-20120238610-A1 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | OHIO UNIVERSITY | 2012-09-20 | — | — | US | disclosed |
| EP-2399578-A1 | Methods and compositions for the treatment of autoimmune and inflammatory diseases associated with toll-like receptors | The Interthyr Corporation (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100004304-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MALIGNANT MELANOMA, BREAST, PROSTATE, COLON, PAPILLARY THYROID AND PANCREATIC CANCER | OHIO UNIVERSITY | 2010-01-07 | — | — | US | disclosed |
| EP-1896015-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTORS | The Interthyr Corporation (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006124676-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTORS | THE INTERTHYR CORPORATION (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060211752-A1 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | BENAVIDES-PERALTA, URUGUAYSITO LORELEY (UY) | 2006-09-21 | — | — | US | disclosed |
| US-20060147508-A1 | Concurrent Enhancement of Skin Penetration of Organic Base Active Agents and Organic Hydroxy Acid Active Agents as Their Ion-Pair Complexes | BIODERM RESEARCH (US) | 2006-07-06 | — | — | US | disclosed |
| US-20040081672-A1 | Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging | GUPTA SHYAM K (US) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211752-A1 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | TLR3, IRF3, TLR4 | LMNA 4799/4885KMT2A 2358/4885TDP1 1417/4885 |
| US-20120238610-A1 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | IRF3, TLR3, TLR4 | LMNA 4804/4885KMT2A 2589/4885TDP1 868/4885 |
| US-20160220536-A1 | USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTOR OVEREXPRESSION | IRF3, TLR3, TLR4 | LMNA 4804/4885KMT2A 2589/4885TDP1 868/4885 |
| US-20100004304-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MALIGNANT MELANOMA, BREAST, PROSTATE, COLON, PAPILLARY THYROID AND PANCREATIC CANCER | STAT3, STAT6, TLR3 | LMNA 4674/4885KMT2A 3831/4885TDP1 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.